Atlas Trials

Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

Clinical trial NCT07627620 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07627620
Sponsor
Hunan Cancer Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Cervical Cancer
Start date
2026-06-30
Primary completion
2027-09-30
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.